Noven Pharma to acquire JDS Pharma for $125M
Noven Pharmaceuticals, a Miami developer of drug-patch technologies and products, agreed to acquire privately held JDS Pharmaceuticals of New York for $125 million. JDS specializes in neurological drugs, including its antidepressant Pexeva and a timed-release form of lithum for bipolar disorder.
JDS was backed by Galen Partners and Altaris Capital Partners.
Next Story: Serus, provider of outsourced manufacturing software, raises $8M
Previous Story: Galen Partners closes $250M healthcare fund
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
